Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25426347 | 1.00 | NNMT (0.56) | NNMTCSNK1A1CLK4HTR2AHTR2C | |
| SCHEMBL25789870 | 0.83 | NNMT (0.55) | NNMT | |
| SCHEMBL25426494 | 0.81 | NNMT (0.47) | NNMTCSNK1A1CLK4 | |
| SCHEMBL25425830 | 0.78 | NNMT (0.58) | NNMT | |
| SCHEMBL25425826 | 0.78 | NNMT (0.58) | NNMT | |
| SCHEMBL25795840 | 0.74 | NNMT (0.38) | NNMT | |
| SCHEMBL25425377 | 0.72 | NNMT (1.00) | NNMT | |
| SCHEMBL13745465 | 0.71 | HTR2A (0.41) | NNMTHTR2AHTR2CHTR2B | |
| SCHEMBL25425626 | 0.67 | NNMT (0.47) | NNMTHTR2AHTR2CHTR2B | |
| SCHEMBL25425630 | 0.67 | NNMT (0.47) | NNMTHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368638-A1 | BICYCLIC INHIBITORS OF NICOTINAMIDE NMETHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | HARVARD COLLEGE (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250340549-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, AND COMPOSITIONS AND USES THEREOF | HARVARD COLLEGE (US) | 2025-11-06 | — | — | US | disclosed |
| CN-119110724-A | Bicyclic inhibitors of nicotinamide N-methyltransferase, compositions and uses thereof | 哈佛大学校长及研究员协会 | 2024-12-10 | — | — | CN | disclosed |
| EP-4456892-A1 | BICYCLIC INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | President and Fellows of Harvard College (US) | 2024-11-06 | — | — | EP | disclosed |
| WO-2023129512-A1 | BICYCLIC INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023129513-A2 | BICYCLIC HETEROAROMATIC INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, AND COMPOSITIONS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023129512-A1 | BICYCLIC INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340549-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, AND COMPOSITIONS AND USES THEREOF | NNMT, NAMPT, NNT | NNMT 1/4885CSNK1A1 2106/4885CLK4 3256/4885 |
| US-20250368638-A1 | BICYCLIC INHIBITORS OF NICOTINAMIDE NMETHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | NNMT, NAMPT, NNT | NNMT 1/4885CSNK1A1 2426/4885CLK4 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.